FYE March 2026 Full-Year Fact Sheet

1. Consolidated Profit and Loss Statement

   The fiscal year (FY) ends on March 31 of each year. 'FY20XX' refers to the fiscal year ending March 31, 20XX unless otherwise stated. Amounts less than the indicated unit are rounded down.

   Net Sales M

   (Net Sales YoY) %

   Cost of Goods Sold M Gross Profit M

   Gross Profit Margin %

   SG&A Expenses M Operating Profit M

   (Operating Profit YoY) %

   Operating Profit Margin % Non-Operating Income M

   Non-Operating Expenses M Ordinary Profit M

   Ordinary Profit Margin %

   FY2020 FY

   A 51,761

   ＋13.7

   22,570

   29,191

   56.4

   18,756

   10,434

   (0.9)

   20.2

   891

   900

   10,425

   20.1

   FY2021 FY

   A 51,286

   (0.9)

   22,622

   28,664

   55.9

   18,296

   10,367

   (0.6)

   20.2

   1,031

   879

   10,519

   20.5

   FY2022 FY

   A 51,469

   ＋0.4

   22,634

   28,835

   56.0

   18,861

   9,973

   (3.8)

   19.4

   316

   285

   10,005

   19.4

   FY2023 FY

   A 51,750

   ＋0.5

   21,855

   29,895

   57.8

   19,057

   10,837

   ＋8.7

   20.9

   293

   224

   10,905

   21.1

   FY2024 FY

   A 51,384

   (0.7)

   20,397

   30,986

   60.3

   20,094

   10,892

   ＋0.5

   21.2

   390

   701

   10,581

   20.6

   FY2025 FY

   A 56,610

   ＋10.2

   22,419

   34,191

   60.4

   21,864

   12,326

   ＋13.2

   21.8

   336

   327

   12,335

   21.8

   Q1 A

   14,616

   ＋4.3

   5,846

   8,769

   60.0

   5,497

   3,272

   ＋2.4

   22.4

   28

   77

   3,223

   22.1

   Q2 A

   14,668

   ＋5.0

   5,880

   8,787

   59.9

   5,439

   3,347

   ＋9.2

   22.8

   66

   13

   3,400

   23.2

   Q3 A

   15,120

   ＋2.0

   6,164

   8,955

   59.2

   5,750

   3,204

   (12.1)

   21.2

   74

   296

   2,983

   19.7

   Q4 A

   14,782

   ＋7.1

   6,121

   8,661

   58.6

   5,879

   2,782

   ＋15.0

   18.8

   221

   23

   2,980

   20.2

   FY2026

   YoY %

   ＋983 ＋7.1

   ＋602 ＋10.9

   ＋380 ＋4.6

   ＋18 ＋0.3

   ＋362 ＋15.0

   ＋148 ＋200.6

   (79) (77.4)

   ＋589 ＋24.7

   FY A

   59,187

   ＋4.6

   24,013

   35,174

   59.4

   22,567

   12,606

   ＋2.3

   21.3

   392

   410

   12,588

   21.3

   YoY %

   ＋2,577 ＋4.6

   ＋1,593 ＋7.1

   ＋983 ＋2.9

   ＋703 ＋3.2

   ＋280 ＋2.3

   ＋56 ＋16.7

   ＋82 ＋25.3

   ＋253 ＋2.1

   H1

   E*1 30,700

   ＋4.8

   13,100

   17,600

   57.3

   13,100

   4,500

   (32.0)

   14.7

   100

   ー

   4,600

   15.0

   H2 E

   32,500

   ＋8.7

   13,500

   19,000

   58.5

   12,800

   6,200

   ＋3.6

   19.1

   100

   100

   6,200

   19.1

   FY2027 FY

   E 63,200

   ＋6.8

   26,600

   36,600

   57.9

   25,900

   10,700

   (15.1)

   16.9

   200

   100

   10,800

   17.1

   YoY %

   ＋4,012 ＋6.8

   ＋2,586 ＋10.8

   ＋1,425 ＋4.1

   ＋3,332 ＋14.8

   (1,906) (15.1)

   (192) (49.0)

   (310) (75.6)

   (1,788) (14.2)

   Extraordinary Profit M

   Extraordinary Loss M

   Net Profit Before Tax M Tax Expenses M

   Net Profit M

   Net Profit Margin %

   3

   4

   10,425

   2,676

   7,748

   15.0

   3

   5,982

   4,540

   2,540

   2,000

   3.9

   44

   8

   10,041

   2,556

   7,484

   14.5

   100

   1,217

   9,789

   2,897

   6,891

   13.3

   13

   19

   10,575

   3,060

   7,515

   14.6

   52

   362

   12,024

   2,707

   9,317

   16.5

   ー

   26

   3,197

   894

   2,302

   15.8

   0

   15

   3,385

   913

   2,472

   16.9

   18

   154

   2,847

   801

   2,046

   13.5

   ー

   33

   2,947

   418

   2,529

   17.1

   (23)

   (293)

   ＋860

   ＋577

   ＋282

   (100.0)

   (89.9)

   ＋41.2

   (362.8)

   ＋12.6

   18

   229

   12,377

   3,027

   9,350

   15.8

   (33)

   (133)

   ＋353

   ＋320

   ＋32

   (64.7)

   (36.8)

   ＋2.9

   ＋11.8

   ＋0.4

   300

   ー

   4,900

   1,400

   3,500

   11.4

   ー

   100

   6,100

   1,600

   4,500

   13.8

   300

   100

   11,000

   3,000

   8,000

   12.7

   ＋281

   (129)

   (1,377)

   (27)

   (1,350)

   ＋1,532.2

   (56.4)

   (11.1)

   (0.9)

   (14.4)

   Basic EPS		96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.24	29.17	36.05		133.30		49.88	64.14	114.02
   Diluted EPS		96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.23	29.16	36.04		133.28		49.88	64.14	114.02

   Proprietary Sales Mix	%	50.7	49.9	52.4	54.9	58.8	57.4	55.6	54.7	56.1	57.5		56.0		57.1	58.7	57.9
   International Sales Mix	%	ー	ー	ー	ー	1.4	1.9	2.4	2.7	2.5	2.3		2.5		2.6	2.8	2.7

   R&D Expenses (A)	M	1,743	1,667	2,159	2,316	2,366	2,851	662	657	898	885	(310)	(25.9)	3,103	＋251	＋8.8	2,239	1,868	4,107	＋1,004	＋32.4
   Clinical Trials & Regulatory Expenses (B)	M	80	69	306	19	70	123	33	28	20	14	(10)	(42.0)	97	(25)	(20.7)	75	45	121	＋23	＋24.0
   R&D Investments (A)+(B)	M	1,823	1,737	2,465	2,335	2,436	2,974	695	685	918	900	(321)	(26.3)	3,200	＋226	＋7.6	2,314	1,913	4,228	＋1,027	＋32.1
   Capital Expenditure	M	2,536	1,382	1,633	976	3,568	1,626	230	225	119	176	(47)	(21.4)	751	(875)	(53.8)	1,283	3,114	4,398	＋3,647	＋485.4
   Depreciation Expenses	M	1,264	1,525	1,611	1,566	1,471	1,779	404	410	417	424	(38)	(8.3)	1,656	(122)	(6.9)	947	1,077	2,025	＋368	＋22.3
   *1 Disclosed on May 7, 2026

2. Consolidated Balance Sheet

   Amounts less than the indicated unit are rounded down.

   		FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
   		FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q4
   											A	vs. Prev. yr-end	%
   Current Assets	M	44,077	44,522	45,153	47,130	42,871	44,336	41,322	44,824	44,652	49,046	＋4,710	＋10.6
   Tangible Fixed Assets	M	11,341	13,111	12,911	12,452	13,434	13,285	13,256	13,145	13,709	13,911	＋626	＋4.7
   Intangible Fixed Assets	M	493	505	1,470	2,414	2,292	1,910	1,808	1,724	1,630	1,564	(345)	(18.1)
   Investments and Others	M	19,089	14,822	13,662	12,643	14,910	15,590	14,782	15,581	16,065	15,688	＋97	＋0.6
   Fixed Assets	M	30,923	28,439	28,044	27,510	30,638	30,786	29,847	30,450	31,405	31,164	＋378	＋1.2
   Total Assets	M	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	76,058	80,211	＋5,088	＋6.8
   Current Liabilities	M	16,093	16,467	14,211	14,381	14,175	14,334	12,034	13,577	12,147	13,597	(736)	(5.1)
   Long-term Liabilities	M	7,500	5,190	4,418	4,063	1,231	874	789	719	715	716	(158)	(18.1)
   Total Liabilities	M	23,594	21,657	18,629	18,445	15,406	15,208	12,823	14,297	12,862	14,314	(894)	(5.9)
   Shareholder's Equity	M	51,618	51,267	54,362	56,265	57,516	58,675	57,289	59,833	61,880	64,409	＋5,733	＋9.8
   Accumulated other comprehensiv	M	(211)	37	205	(69)	585	1,239	1,056	1,131	1,286	1,441	＋201	＋16.3
   Share Warrant	M	ー	ー	ー	ー	ー	ー	ー	12	29	47	＋47	ー
   Net Assets	M	51,406	51,304	54,567	56,195	58,102	59,914	58,346	60,977	63,196	65,897	＋5,983	＋10.0
   Total Liabilities and Net Assets	M	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	76,058	80,211	＋5,088	＋6.8

   Cash and Deposits	M	9,555	13,708	16,058	18,357	12,669	11,014	7,467	9,630	8,644	12,494	＋1,479	＋13.4
   Accounts Receivables	M	13,762	13,145	12,437	13,223	13,283	13,830	14,170	14,435	15,115	14,550	＋720	＋5.2
   Inventory	M	18,187	15,987	14,850	13,142	15,154	17,961	18,188	19,146	19,287	20,129	＋2,168	＋12.1
   Accounts Payables	M	4,081	2,872	3,287	3,429	4,254	4,358	3,782	4,455	3,916	4,432	＋74	＋1.7
   Retained Earnings	M	35,912	35,352	38,890	42,741	47,291	53,455	52,035	54,507	56,554	59,083	＋5,627	＋10.5
   Interest-Bearing Debt	M	11,538	10,396	8,352	6,883	4,634	3,973	3,864	3,812	3,458	3,117	(856)	(21.6)
   Net Debt	M	1,983	(3,311)	(7,705)	(11,473)	(8,034)	(7,041)	(3,602)	(5,818)	(5,185)	(9,377)	(2,336)	＋33.2
   Invested Capital*1	M	63,156	61,663	62,714	63,148	62,151	62,648	61,154	63,645	65,338	67,526	＋4,877	＋7.8
   Working Capital*2	M	27,868	26,260	24,000	22,937	24,183	27,433	28,577	29,125	30,486	30,247	＋2,814	＋10.3

   *1 A sum of interest-bearing debt and shareholder's equity

   *2 Accounts receivables + Inventory - Accounts payables

3. Consolidated Cash Flows

   Amounts less than the indicated unit are rounded down.

   		FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
   		FY A	FY A	FY A	FY A	FY A	FY A		FY A
   Operating Cash Flows	M	7,096	11,432	10,246	11,201	6,918	9,113		8,172
   Investing Cash Flows	M	(4,419)	(3,731)	(1,131)	(2,461)	(4,056)	(1,801)		(2,048)
   Financing Cash Flows	M	(1,136)	(3,720)	(6,804)	(6,476)	(8,553)	(9,040)		(4,581)
   Others	M	(4)	172	38	35	4	74		(62)
   Net change in cash and cash equivalents	M	1,536	4,153	2,349	2,298	(5,688)	(1,654)		1,479
   Cash and cash equivalents at end of period	M	9,555	13,708	16,058	18,357	12,669	11,014		12,494

4. Financial Indicators

   Amounts less than the indicated unit are rounded down.

   		FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026							FY2027
   		FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q4 A		FY A		H1 E	H2 E	FY E
   No. of Issued Shares at YR-End (incl. treasury shares)	K	85,419	85,419	85,419	82,919	75,758	75,758	71,300	71,300	71,300	71,300		71,300		ー	ー	ー
   No. of Treasury Shares at YR-End*1	K	5,165	5,050	5,500	4,999	829	5,661	1,185	1,143	1,144	1,145		1,145		ー	ー	ー
   Ave No. of O/S Shares during the period*2	K	80,251	80,322	80,367	78,116	76,122	70,890	70,102	70,156	70,155	70,155		70,142		ー	ー	ー
   Basic EPS*3		96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.24	29.17	36.05		133.30		49.88 ーーーーーーー ー	64.14 ーーーーーーー ー	114.02
   BPS		640.54	638.36	682.79	721.20	775.43	854.74	832.15	868.99	900.37	938.65		938.65				996.36
   DPS		29.00	49.00	38.00	38.00	42.00	53.00	ー	ー	ー	ー		54.00				56.00
   DOE %		4.5	7.7	5.6	5.3	5.4	6.2	ー	ー	ー	ー		5.8				5.6
   Payout Ratio %		30.0	196.7	40.8	43.1	42.5	40.3	ー	ー	ー	ー		40.5				49.1
   ROE %		15.8	3.9	14.1	12.4	13.2	15.8	ー	ー	ー	ー		14.9				11.8
   ROA %		14.6	14.2	13.7	14.8	14.3	16.6	ー	ー	ー	ー		16.2				13.3
   ROIC*4 %		12.1	11.5	11.1	11.9	12.1	13.7	ー	ー	ー	ー		13.4				10.7
   Capital-to-Asset Ratio %		68.5	70.3	74.5	75.3	79.0	79.8	82.0	81.0	83.0	82.1		82.1				85.1
   Receivabes Turnover Period	Day	91	96	91	90	94	89	ー	ー	ー	ー		90		ー	ー	90
   Inventory Turnover Period	Day	285	276	249	234	253	283	ー	ー	ー	ー		306		ー	ー	275
   Payables Turnover Period	Day	58	56	50	56	69	70	ー	ー	ー	ー		68		ー	ー	53
   Cash Conversion Cycle	Day	319	315	290	268	279	302	ー	ー	ー	ー		328		ー	ー	313
   Number of Employees (Consolidated) Person		1,074	1,167	1,205	1,166	1,216	1,250	ー	ー	ー	ー		1,293		ー	ー	ー

   *1 Company shares held by the BIP Trust for directors and Company shares held by the Trust for the Trust-type Employee Shareholding Incentive Plan (E-Ship) are included in treasury shares. (E-Ship terminated on July 29, 2021)

   *2 Excluding treasury shares. Values for each Q are for the accounting period

   *3 EPS after taking into account the stock split. A 1:2 stock split was carried out in Jan. 2018. In light of this, EPS for FY2018 is calculated assuming that the stock split took place at the beginning of the fiscal year

   *4 Denominator profit is operating profit after tax. After-tax operating profit = operating profit *(1 - effective tax rate (30.62%))

5. Sales by Product

   FY2020

   FY2021

   FY2022

   FY2023

   FY2024

   FY2025

   FY2026

   Amounts less than the indicated unit are rounded down.

   FY2027

   Pacemaker*6 M

   ICD*6 M

   Others M

   Cardiac Rhythm Management TTL M (CRM YoY) %

   EP Catheter M

   ABL Catheter M

   Others M

   EP/Ablation TTL M

   (EP/ABL YoY) %

   Artificial Heart Valve M

   Vascular Graft M

   Blood Purification*1 M

   Others*3*5 M

   Cardiovascular*４ TTL M (CV YoY) %

   FY A

   5,682

   5,960

   223

   11,866

   ＋102.4

   17,915

   1,421

   5,358

   24,696

   ＋7.1

   259

   8,879

   994

   32

   10,166

   (13.3)

   FY A

   5,996

   7,001

   250

   13,248

   ＋11.7

   17,314

   1,047

   5,501

   23,863

   (3.4)

   ー

   9,039

   ー

   929

   9,969

   (1.9)

   FY A

   5,899

   6,747

   330

   12,977

   (2.0)

   18,412

   1,232

   5,455

   25,099

   ＋5.2

   ー

   9,368

   ー

   748

   10,117

   ＋1.5

   FY A

   4,979

   7,049

   374

   12,403

   (4.4)

   19,654

   1,011

   5,626

   26,292

   ＋4.8

   ー

   10,353

   ー

   423

   10,776

   ＋6.5

   FY A

   5,241

   7,857

   402

   13,501

   ＋8.9

   21,211

   840

   2,197

   24,249

   (7.8)

   ー

   10,956

   ー

   449

   11,406

   ＋5.9

   FY A

   4,506

   8,296

   464

   13,267

   (1.7)

   22,543

   647

   4,654

   27,845

   ＋14.8

   ー

   11,688

   ー

   517

   12,206

   ＋7.0

   Q1 A

   1,049

   2,136

   199

   3,386

   (2.4)

   5,653

   87

   1,535

   7,276

   ＋2.5

   ー

   2,848

   ー

   161

   3,010

   ＋8.1

   Q2 A 960

   2,094

   225

   3,280

   ＋0.8

   5,708

   73

   1,647

   7,430

   ＋5.8

   ー

   2,685

   ー

   240

   2,926

   ＋1.9

   Q3 A 972

   2,145

   210

   3,329

   (1.9)

   5,493

   83

   1,620

   7,197

   (0.4)

   ー

   3,217

   ー

   186

   3,404

   ＋1.9

   Q4 A 882

   1,948

   230

   3,061

   (2.8)

   5,533

   66

   1,605

   7,205

   ＋11.0

   ー

   3,153

   ー

   162

   3,316

   ＋3.3

   YoY

   (28)

   (163)

   ＋105

   (86)

   ＋439

   (36)

   ＋308

   ＋712

   ー

   ＋75

   ー

   ＋30

   ＋106

   % (3.2)

   (7.7)

   ＋84.0

   (2.8)

   ＋8.6

   (35.3)

   ＋23.8

   ＋11.0

   ー

   ＋2.5

   ー

   ＋23.2

   ＋3.3

   FY A

   3,865

   8,324

   867

   13,057

   (1.6)

   22,389

   311

   6,408

   29,109

   ＋4.5

   ー

   11,905

   ー

   752

   12,657

   ＋3.7

   YoY (641)

   ＋27

   ＋403

   (210)

   (153)

   (336)

   ＋1,753

   ＋1,264

   ー

   ＋216

   ー

   ＋234

   ＋451

   % (14.2)

   ＋0.3

   ＋86.9

   (1.6)

   (0.7)

   (51.9)

   ＋37.7

   ＋4.5

   ー

   ＋1.9

   ー

   ＋45.4

   ＋3.7

   H1 E

   1,730

   4,320

   470

   6,520

   (2.2)

   11,810

   200

   3,690

   15,700

   ＋6.8

   ー

   5,760

   ー

   340

   6,100

   ＋2.7

   H2 E

   1,770

   4,280

   500

   6,550

   ＋2.5

   11,890

   160

   4,120

   16,170

   ＋12.3

   ー

   6,700

   ー

   380

   7,080

   ＋5.3

   FY E

   3,500

   8,600

   970

   13,070

   ＋0.1

   23,700

   360

   7,810

   31,870

   ＋9.5

   ー

   12,460

   ー

   720

   13,180

   ＋4.1

   YoY (365)

   ＋275

   ＋102

   ＋12

   ＋1,310

   ＋48

   ＋1,401

   ＋2,760

   ー

   ＋554

   ー

   (32)

   ＋522

   % (9.4)

   ＋3.3

   ＋11.8

   ＋0.1

   ＋5.9

   ＋15.6

   ＋21.9

   ＋9.5

   ー

   ＋4.7

   ー

   (4.3)

   ＋4.1

   Neurovascular*5*7 M

   Neurovascular TTL M (NV YoY) %

   Gastrointestinal M

   Others*3 M

   Gastrointestinal*2*3 TTL M (GI YoY) %

   Consolidated Net Sales M (Consolidated Net Sales YoY) %

   *1 Included in "Others" since FY2021

   ーーー

   132

   4,900

   5,032

   ＋3.3

   51,761

   ＋13.7

   ーーー

   247

   3,957

   4,204

   (16.5)

   51,286

   (0.9)

   12

   12

   ー

   453

   2,808

   3,261

   (22.4)

   51,469

   ＋0.4

   230

   230

   ＋1,753.6

   654

   1,394

   2,048

   (37.2)

   51,750

   ＋0.5

   912

   912

   ＋296.7

   925

   388

   1,314

   (35.8)

   51,384

   (0.7)

   1,842

   1,842

   ＋101.9

   1,345

   103

   1,448

   ＋10.2

   56,610

   ＋10.2

   562

   562

   ＋61.9

   352

   28

   380

   ＋23.9

   14,616

   ＋4.3

   624

   624

   ＋38.0

   394

   12

   406

   ＋9.0

   14,668

   ＋5.0

   726

   726

   ＋47.7

   463

   ー

   463

   ＋24.6

   15,120

   ＋2.0

   748

   748

   ＋35.9

   451

   0

   451

   ＋13.7

   14,782

   ＋7.1

   ＋197 ＋35.9

   ＋197 ＋35.9

   ＋54 ＋13.7

   0 (40.0)

   ＋54 ＋13.7

   ＋983 ＋7.1

   2,661

   2,661

   ＋44.5

   1,661

   40

   1,701

   ＋17.4

   59,187

   ＋4.6

   ＋819 ＋44.5

   ＋819 ＋44.5

   ＋316 ＋23.5

   (63) (61.2)

   ＋252 ＋17.4

   ＋2,577 ＋4.6

   1,450

   1,450

   ＋22.1

   930

   ー

   930

   ＋18.1

   30,700

   ＋4.8

   1,680

   1,680

   ＋14.0

   1,020

   ー

   1,020

   ＋11.5

   32,500

   ＋8.7

   3,130

   3,130

   ＋17.6

   1,950

   ー

   1,950

   ＋14.6

   63,200

   ＋6.8

   ＋468 ＋17.6

   ＋468 ＋17.6

   ＋288 ＋17.4

   (40) (100.0)

   ＋248 ＋14.6

   ＋4,012 ＋6.8

   *2 Renamed from "Transvascular Intervention" to "Gastrointestinal/PI" since FY2023

   *3 Renamed from "Gastrointestinal/PI" to "Gastrointestinal" since FY2024 as PI businesses are downsized. Its subcategory "PI-related" is renamed to "Others". Sales of structural heart disease-related is moved to "Cardiovascular, Others" (Reclassifications)

   *4 Renamed from "Cardiovascular Surgery" to "Cardiovascular" since FY2024

   *5 Sales of neurovascular-related is moved from "Cardiovascular, Others" to an new independent category of "Cardiovascular, Neurovascular" (Reclassifications)

   *6 Sales of left ventricular pacing lead is moved from "ICD" to "Pacemaker" since FY2024 (Reclassifications)

   *7 Sales of neurovascular in the sub-groupe of CV is moved to a new independent main groupe (Reclassifications)

   *8 Reclassifications regarding *3, *5, *6, and *7 are retroactively applied to FY2021 and onward.

6. Products Included in Product Categories (As of Mar. 2026)

*Listed in descending order of composition ratio. *Red text indicates items defined as "Core Products." *Underlined text indicates proprietary products.